Wright Investors Service Inc. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 249.9% during the 2nd quarter, HoldingsChannel reports. The firm owned 44,960 shares of the biopharmaceutical company’s stock after purchasing an additional 32,110 shares during the period. Gilead Sciences comprises about 1.2% of Wright Investors Service Inc.’s investment portfolio, making the stock its 22nd biggest position. Wright Investors Service Inc.’s holdings in Gilead Sciences were worth $3,037,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Creative Financial Designs Inc. ADV lifted its position in shares of Gilead Sciences by 55.9% during the 1st quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 165 shares in the last quarter. Trustcore Financial Services LLC purchased a new position in shares of Gilead Sciences during the 1st quarter valued at about $34,000. Weaver Consulting Group purchased a new position in shares of Gilead Sciences during the 1st quarter valued at about $34,000. Legacy Advisors LLC purchased a new position in shares of Gilead Sciences during the 2nd quarter valued at about $37,000. Finally, Founders Capital Management lifted its position in shares of Gilead Sciences by 50.0% during the 1st quarter. Founders Capital Management now owns 600 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 200 shares in the last quarter. 78.87% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ GILD traded up $0.39 during trading hours on Thursday, reaching $63.51. The company’s stock had a trading volume of 1,895,115 shares, compared to its average volume of 6,220,770. The business’s 50-day moving average is $66.33. The company has a quick ratio of 3.67, a current ratio of 3.76 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 1 year low of $60.32 and a 1 year high of $79.61. The stock has a market cap of $81.03 billion, a P/E ratio of 10.33, a price-to-earnings-growth ratio of 3.04 and a beta of 1.16.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.97%. The ex-dividend date of this dividend is Thursday, September 12th. Gilead Sciences’s payout ratio is 40.98%.
In other Gilead Sciences news, EVP Brett A. Pletcher sold 5,816 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $68.75, for a total value of $399,850.00. Following the sale, the executive vice president now owns 27,198 shares of the company’s stock, valued at approximately $1,869,862.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Brett A. Pletcher sold 7,200 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $65.07, for a total value of $468,504.00. Following the completion of the sale, the executive vice president now directly owns 34,398 shares in the company, valued at approximately $2,238,277.86. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.
GILD has been the topic of a number of analyst reports. Mizuho set a $88.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research report on Monday, July 15th. Jefferies Financial Group set a $95.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research report on Monday, July 15th. Goldman Sachs Group cut Gilead Sciences from a “neutral” rating to a “sell” rating and lowered their price objective for the company from $70.00 to $60.00 in a research report on Tuesday, May 28th. ValuEngine raised Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, BMO Capital Markets set a $82.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company. Gilead Sciences presently has an average rating of “Buy” and a consensus price target of $82.29.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.